Anthony Mills Selected Research

elvitegravir

11/2016	Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
8/2015	Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
3/2014	A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.
5/2013	A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
6/2012	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anthony Mills Research Topics

Disease

12	Infections 08/2019 - 06/2012
4	Exanthema (Rash) 06/2012 - 01/2010
3	HIV Infections (HIV Infection) 01/2021 - 01/2005
2	Hepatitis B 11/2017 - 11/2016
2	Nausea 11/2017 - 06/2012
2	Dizziness (Lightheadedness) 06/2012 - 07/2011
1	Hemophilia A (Haemophilia) 01/2022
1	Hemorrhage 01/2022
1	Rare Diseases (Rare Disease) 01/2022
1	Fatigue 11/2021
1	Substance-Related Disorders (Drug Abuse) 01/2020
1	Coinfection 01/2020
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2019
1	Urticaria (Hives) 01/2017
1	Chronic Hepatitis B 11/2016
1	Fibrosis (Cirrhosis) 08/2015
1	Proteinuria 08/2015
1	Mental Disorders (Mental Disorder) 08/2015
1	Hyperbilirubinemia 02/2013
1	Sleep Initiation and Maintenance Disorders (Insomnia) 06/2012

Drug/Important Bio-Agent (IBA)

9	Emtricitabine (Emtriva)FDA Link 01/2018 - 06/2012
8	tenofovir alafenamideIBA 01/2018 - 08/2015
8	Tenofovir (Viread)FDA Link 11/2017 - 06/2012
5	efavirenz (Sustiva)FDA Link 01/2017 - 07/2011
5	elvitegravirIBA 11/2016 - 06/2012
4	CobicistatIBA 11/2016 - 06/2012
4	TabletsIBA 11/2016 - 06/2012
3	dolutegravirIBA 01/2018 - 01/2017
3	bictegravirIBA 01/2018 - 01/2017
3	Rilpivirine (TMC-278)IBA 01/2017 - 07/2011
2	Lamivudine (Epivir)FDA Link 01/2018 - 11/2017
2	abacavir (Ziagen)FDA Link 01/2018 - 11/2017
2	Pharmaceutical PreparationsIBA 11/2017 - 01/2017
2	etravirine (TMC-125)FDA Link 10/2010 - 01/2010
1	Factor VII (Proconvertin)IBA 01/2022
1	Rituximab (Mabthera)FDA Link 01/2022
1	AutoantibodiesIBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	vesatolimodIBA 01/2021
1	Ribavirin (Virazole)FDA LinkGeneric 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2019
1	InterferonsIBA 01/2019
1	LipidsIBA 01/2018
1	RNA (Ribonucleic Acid)IBA 11/2017
1	HLA-B Antigens (HLA-B)IBA 11/2017
1	emtricitabine tenofovir alafenamideIBA 11/2016
1	SofosbuvirIBA 08/2015
1	daclatasvirIBA 08/2015
1	ProdrugsIBA 08/2015
1	Protease Inhibitors (Protease Inhibitor)IBA 08/2015
1	Transaminases (Aminotransferases)IBA 02/2013
1	Integrase InhibitorsIBA 06/2012
1	RacivirIBA 06/2012
1	Testosterone (Sustanon)FDA Link 01/2005

Therapy/Procedure

6	Therapeutics 11/2021 - 08/2015
2	Injections 11/2021 - 08/2019